Irinotecan
生产企业：Pfizer inc, Accord healthcare inc，另有 14 家
Irinotecan is an antineoplastic enzyme inhibitor used to treat metastatic carcinoma of the colon or rectum.
Irinotecan is an antineoplastic enzyme inhibitor used to treat metastatic carcinoma of the colon or rectum.
Irinotecan inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex. The formation of this ternary complex interferes with the moving replication fork, which induces replication arrest and lethal double-stranded breaks in DNA. As a result, DNA damage is not efficiently repaired and apoptosis (programmed cell death) occurs.
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
共 13 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
